<p>In our virtual experiments, we set the challenge dose equal to the <i>ID</i><sub>50</sub>, and assumed that the vaccine efficacy was 67% (dotted lines), 80% (dashed lines), or 90% (solid lines). The graph shows the statistical power of the repeated low-dose challenge design (black lines) and the single low-dose challenge design (green lines) for a given number of animals per group as determined from 100,000 virtual experiments. If the vaccine is 90% effective, the statistical power of the repeated low-dose challenge design is higher than 95% with only five animals per group, as compared to only 15% for the single low-dose challenge design.</p
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
<p>The plots show the number of successful trials out of 100 simulated trial runs (y-axis) for diffe...
<p>(a) The dose-response curves for the wild type in blue (<i>r</i>(<i>c</i>) = 0.6(1−tanh(15(<i>c</...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
<p>Power estimates are shown as a function of the effect size. The <i>in silico</i> challenge data a...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
<div><p>(A) Susceptibility distributions for different levels of heterogeneity, measured by the coef...
<p>For this plot we assumed trials with vaccine efficacies of <i>VE<sub>S</sub> =</i> 0.67 (dotted l...
<p>Colors in each panel represent the cumulative incidence ratio, comparing cumulative incidence amo...
<p>Figure shows designs for single (A) and repeated (B) low-dose challenge designs. Small arrows den...
Trials in macaque models play an essential role in the evaluation of biomedical interventions that a...
<p>Simulations were performed for each combination of vaccine type (erythrocytic or hepatic), effica...
Repeated low-dose (RLD) challenge designs are important in HIV vaccine research. Current methods for...
<p>(<b>A</b>) Kaplan-Meier analysis of the three test groups. The percentage of animals remaining un...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
<p>The plots show the number of successful trials out of 100 simulated trial runs (y-axis) for diffe...
<p>(a) The dose-response curves for the wild type in blue (<i>r</i>(<i>c</i>) = 0.6(1−tanh(15(<i>c</...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
<p>Power estimates are shown as a function of the effect size. The <i>in silico</i> challenge data a...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
<div><p>(A) Susceptibility distributions for different levels of heterogeneity, measured by the coef...
<p>For this plot we assumed trials with vaccine efficacies of <i>VE<sub>S</sub> =</i> 0.67 (dotted l...
<p>Colors in each panel represent the cumulative incidence ratio, comparing cumulative incidence amo...
<p>Figure shows designs for single (A) and repeated (B) low-dose challenge designs. Small arrows den...
Trials in macaque models play an essential role in the evaluation of biomedical interventions that a...
<p>Simulations were performed for each combination of vaccine type (erythrocytic or hepatic), effica...
Repeated low-dose (RLD) challenge designs are important in HIV vaccine research. Current methods for...
<p>(<b>A</b>) Kaplan-Meier analysis of the three test groups. The percentage of animals remaining un...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
<p>The plots show the number of successful trials out of 100 simulated trial runs (y-axis) for diffe...
<p>(a) The dose-response curves for the wild type in blue (<i>r</i>(<i>c</i>) = 0.6(1−tanh(15(<i>c</...